Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)
about
Fas-associated factor-1 inhibits nuclear factor-kappaB (NF-kappaB) activity by interfering with nuclear translocation of the RelA (p65) subunit of NF-kappaBFLICE-inhibitory proteins: regulators of death receptor-mediated apoptosisThe Fas-associated death domain protein suppresses activation of NF-kappa B by LPS and IL-1 betaA novel kinase inhibitor of FADD phosphorylation chemosensitizes through the inhibition of NF-κBCellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complexModulating cell-to-cell variability and sensitivity to death ligands by co-drugging.Deoxycholic acid induces the overexpression of intestinal mucin, MUC2, via NF-kB signaling pathway in human esophageal adenocarcinoma cells.The linear ubiquitin chain assembly complex regulates TRAIL-induced gene activation and cell death.Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism.Human MUC1 carcinoma-associated protein confers resistance to genotoxic anticancer agents.TRAIL/Apo-2L: mechanisms and clinical applications in cancer.TNF ligands and receptors--a matter of life and death.Bortezomib sensitizes malignant human glioma cells to TRAIL, mediated by inhibition of the NF-{kappa}B signaling pathway.Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation.Fas (CD95) induces macrophage proinflammatory chemokine production via a MyD88-dependent, caspase-independent pathwayDeath receptor-based enrichment of Cas9-expressing cellsSarcopenia and cachexia: the adaptations of negative regulators of skeletal muscle mass.Control of Mitochondrial Dynamics by Fas-induced Caspase-8 Activation in Hippocampal NeuronsThe inhibition of the apoptosis pathway by the Coxiella burnetii effector protein CaeA requires the EK repetition motif, but is independent of survivinInvestigation of the susceptibility of human cell lines to bovine herpesvirus 4 infection: demonstration that human cells can support a nonpermissive persistent infection which protects them against tumor necrosis factor alpha-induced apoptosis.Overcoming resistance to TRAIL-induced apoptosis in solid tumor cells by simultaneously targeting death receptors, c-FLIP and IAPs.Therapeutic applications of TRAIL receptor agonists in cancer and beyond.Non-apoptotic signaling pathways activated by soluble Fas ligand in serum-starved human fibroblasts. Mitogen-activated protein kinases and NF-kappaB-dependent gene expression.The anticancer drug mithramycin A sensitises tumour cells to apoptosis induced by tumour necrosis factor (TNF).Cell death-independent activities of the death receptors CD95, TRAILR1, and TRAILR2.CD40-directed scFv-TRAIL fusion proteins induce CD40-restricted tumor cell death and activate dendritic cells.The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL.Saquinavir-NO-targeted S6 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL.NF-kappaB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling.Itch/AIP4-independent proteasomal degradation of cFLIP induced by the histone deacetylase inhibitor SAHA sensitizes breast tumour cells to TRAIL.Proteasome inhibition results in TRAIL sensitization of primary keratinocytes by removing the resistance-mediating block of effector caspase maturationDoxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL.Fas/CD95-mediated apoptosis of type II cells is blocked by Toxoplasma gondii primarily via interference with the mitochondrial amplification loop.Mitotic arrest and JNK-induced proteasomal degradation of FLIP and Mcl-1 are key events in the sensitization of breast tumor cells to TRAIL by antimicrotubule agents.Oligomerized tumor necrosis factor-related apoptosis inducing ligand strongly induces cell death in myeloma cells, but also activates proinflammatory signaling pathways.TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling.Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B.Role of phosphatidylinositol-3 kinase/Akt pathway in bladder cancer cell apoptosis induced by tumor necrosis factor-related apoptosis-inducing ligand.Functional expression of a proliferation-related ligand in hepatocellular carcinoma and its implications for neovascularization.Fas-associated death-domain protein inhibits TNF-alpha mediated NF-kappaB activation in cardiomyocytes.
P2860
Q24299181-90EDF7B9-04B3-4155-8B32-393688254918Q24548247-B58BD42E-BB63-430E-BF36-7F73CC974FB2Q24551184-0D6E51DF-3CA3-48A6-A6A0-94CDC7F452E5Q24635114-58E114DB-CF15-4A3E-A562-4453A007801BQ28209029-FDF97230-0E98-4BC5-B38B-517F56BCE1E9Q30544925-3BA14C72-4235-4479-B264-10B55739E01EQ33384875-538F8857-AD13-4524-9BEB-9033CC902F7AQ33625907-4915B633-8DFC-4F4B-A8E3-348041441C90Q33695961-F09241E4-2ABC-4E9A-BA11-695D4229CF3DQ34440814-79476916-9E40-4580-BC0C-7A606476EECCQ34482821-0144E2F9-1346-4F62-9F55-8C2EEDF68449Q34542205-6A253971-9187-424B-BB7C-47E24D243DDCQ34786865-DBB21E1E-34F9-4E38-A731-A69B93EA9CDDQ35082212-E53D766B-3B9A-491B-94BD-C50041DEB2D1Q35820717-F0DE41A1-1683-4C5B-8B1B-3110931A6605Q35925498-03362387-C484-43BB-8609-5E5C5CB530CEQ36028202-A808A252-D45F-43F8-AE33-6B0ACB643003Q36087586-BF14B1D9-6B70-418B-9461-0B7602B3D915Q36913235-99B99881-DD11-4406-AC7C-70A3F2E0487BQ36954898-6177364A-EA5D-496E-930C-6716267AAC23Q36992161-703723FF-E2B8-4A54-B700-9D715B60D75AQ37114025-68A4E360-E558-4E1B-9041-2B05C0E71A8FQ38295816-347256BB-778E-4D25-A095-E3CE5EAEA6B3Q38795149-31545AC2-55DB-4C72-8B21-5EF8D31A923AQ39013916-646DC781-4023-40CA-BF83-56C938E18104Q39063100-57DA31CB-CD82-428A-8D2F-D54C4AB76DA5Q39253903-E3ABFFC7-0703-458B-A21A-AF056A7EE1F7Q39389293-6F009016-B73C-4C58-9843-82F1BFABA62FQ39459534-F9A227CD-A0B7-49E0-8F65-8231FC020739Q39627572-107E4337-B99F-4C30-9CFB-FA7644E5968BQ39698787-EBA0545E-9569-4636-A537-CCA346E87E16Q39711397-0D3187B8-013C-4ECE-8515-080E4CECC268Q39758145-C813FDC5-F6B3-4868-B3A1-8B54BC2253B9Q39770080-0D785E39-74C9-4579-8AA7-6B96AD82E78CQ39778244-773047E6-6F66-477E-82EA-97C0CC0987D8Q39832953-FCD74AB4-00F6-4956-A259-5BFB7F271895Q39899167-14944DE2-B7DD-44C0-AC1A-B7F46A17D574Q40230098-5FA72796-2F5F-463B-A423-8A1B08F5B1CAQ40386392-61515703-F561-4111-A594-8860C81BC36DQ40404611-0C14CDFC-591E-4648-AFDD-BB97720D11AD
P2860
Inhibition of death receptor-mediated gene induction by a cycloheximide-sensitive factor occurs at the level of or upstream of Fas-associated death domain protein (FADD)
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@ast
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@en
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@nl
type
label
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@ast
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@en
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@nl
prefLabel
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@ast
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@en
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@nl
P2093
P3181
P356
P1476
Inhibition of death receptor-m ...... ed death domain protein (FADD)
@en
P2093
F Muhlenbeck
G Schubert
P Scheurich
R Schwenzer
P304
P3181
P356
10.1074/JBC.M000811200
P407
P577
2000-08-11T00:00:00Z